Taking angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) is associated with a decreased risk of colorectal cancer within three years of colonoscopy, according to the results of a new study. By inhibiting or blocking angiotensin, a protein that raises blood pressure by constricting the arteries, ACE inhibitors and ARBs treat heart disease, heart failure, and high blood pressure. Whether ACE inhibitors and ARBs can also play a role in cancer prevention, howeve...
The FDA has approved oral decitabine/cedazuridine (Inqovi®, Astex Pharmaceuticals, Inc.) for the treatment of adult patients with either newly diagnosed or previously treated de novo or secondary myelodysplastic syndrome (MDS) whose disease is classified as one of the following French-American-British subtypes: refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, or chronic myelomonocytic leukemia (CMML). Decitabine/cedazuridine is indicated for pa...
In patients with cancer who develop venous thromboembolism (VTE), cancer type plays a significant role in the risk of VTE recurrence after anticoagulation. A condition involving the formation of a blood clot that starts in a vein, VTE can negatively impact the clinical outcomes of patients undergoing cancer treatment. While anticoagulation therapies, including apixaban and rivaroxaban, are mainstays of treatment, patients with cancer experience higher rates of anticoagulation failure and bleedin...
The FDA has approved a subcutaneous injection of pertuzumab/trastuzumab/hyaluronidase-zzxf (Phesgo®, Genentech, Inc.) for adults with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. This fixed-dose combination treatment is approved in combination with chemotherapy as neoadjuvant therapy for patients who have locally advanced, inflammatory, or early stage (either greater than 2 cm in diameter or node positive) disease; as adjuvant treatment for patients with HER2-positive ...
In this interview with i3 Health, Suzanne Jan de Beur, MD, discusses the recent approval of burosumab-twza (Crysvita®, Ultragenyx Pharmaceutical, Inc.), for patients with tumor-induced osteomalacia (TIO) whose tumors are unable to be localized or resected. Dr. Jan de Beur, lead investigator of one of the phase 2 clinical trials on which the approval was based, explains the challenges involved in diagnosing and treating TIO and discusses the significance of the approval of burosumab-twza for pati...